# Acetaminophen Intake and Risk of Asthma, Hay Fever and Eczema in Early Adolescence

Emilija Vlaski<sup>1</sup>, Katerina Stavric<sup>2</sup>, Rozalinda Isjanovska<sup>3</sup>, Lidija Seckova<sup>1</sup>, and Milica Kimovska<sup>1</sup>

<sup>1</sup> Department of Pulmonology and Allergology, University Children's Hospital, Skopje, Republic of Macedonia

<sup>2</sup> Department of Immunology, University Children's Hospital, Skopje, Republic of Macedonia

<sup>3</sup> Institute of Epidemiology, Biostatistics and Medical Informatics, Skopje, Republic of Macedonia

Received: 14 February 2007; Accepted: 26 May 2007

## ABSTRACT

A positive association between acetaminophen intake and allergic diseases has recently been reported in developed countries with impaired oxidant/antioxidant balance and promotion of atopy as proposed underlying mechanisms. The aim of the study was to explore the relationship between acetaminophen intake and asthma, hay fever, and eczema in The Republic of Macedonia as a country with acetaminophen intake not physiciancontrolled, high passive smoke exposure and dietary antioxidant intake, and moderately low prevalence of allergic diseases.

Self-reported data obtained through the standardized International Study of Asthma and Allergies in Childhood Phase Three written questionnaires of 3026 adolescents aged 13/14 years from randomly selected schools in Skopje, the capital of Macedonia, were used. The frequency of current acetaminophen intake -both unadjusted and adjusted for confounding factors- was correlated to current and ever-diagnosed asthma, hay fever and eczema by odds ratios (OR, 95% CI) in binary logistic regression.

Use of acetaminophen at least once monthly increased the risk of current wheeze (adjusted OR 2.04, 1.31-3.20 p = 0.002), asthma 'ever' (adjusted OR 2.77, 1.06-7.26 p=0.039), current allergic rhinoconjunctivitis (adjusted OR 2.95, 1.79-4.88 p=0.000) and hay fever 'ever' (adjusted OR 2.25, 1.36-3.70 p=0.002). A significant association between frequent acetaminophen intake and atopic eczema and also between infrequent acetaminophen intake and investigated allergic diseases was not established.

The findings suggest an increased risk of asthma and hay fever, but not atopic eczema associated with frequent acetaminophen use in a developing country.

Key words: Acetaminophen; Adolescent; Asthma; Atopic eczema; Hay fever

#### INTRODUCTION

Compared to the great number of countries that have participated in the International Study of Asthma and Allergies in Childhood (ISAAC), The Republic of

Copyright© 2007, IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY. All rights reserved.

**Corresponding Author:** Emilija Vlaski, MD; Department of Pulmonology and Allergology, University Children's Hospital, Faculty of Medicine, Vodnjanska 17, 1000 Skopje, The Republic of Macedonia. Tel: (+389 2) 3147 475, Fax: (+389 2) 3129 027, E-mail: vlaskie@sonet.com.mk

Macedonia appears to have moderately low prevalence rates of asthma and hay fever and a low prevalence of eczema.<sup>1-5</sup>

An ecological study using data from the European Community Respiratory Health Survey (ECRHS) and ISAAC has shown a positive association between acetaminophen (paracetamol) sales and prevalence rates of asthma, allergic rhinitis and atopic eczema in adults and children.<sup>6</sup> Moreover, an increased risk of wheeze in early childhood <sup>7</sup> and an increased risk of asthma and elevated blood total IgE in school age children <sup>8</sup> related to a prenatal paracetamol exposure have been found with a proportion of asthma attributable to paracetamol use, assuming a causal relationship, of 1% and 7%, respectively.

Acetaminophen may deplete stores of glutathione, whose reduced form is one of the major antioxidants present in the airways and plays a role in drug detoxification, thus leading to oxidant damage in the lung, inflammation and bronchial hyperresponsiveness.

<sup>6,9,10</sup> Furthermore, acetaminophen is hypothesized to promote atopy through defective antigen processing by decreased glutathione level<sup>10</sup> or through a lack of suppression of cyclooxygenase pathway and an increased prostaglandin E2 production,<sup>11,12</sup> thereby promoting T-helper cell 2-type cytokine responses.<sup>10,13</sup> The least developed is the theory of an IgE-mediated mechanism with acetaminophen as the antigenic agent.<sup>10,13</sup> There is evidence that respiratory antioxidant defense may also be impaired if dietary antioxidant intake (vitamin C, vitamin E, carotene, flavonoids, trace elements) is inadequate or if the oxidant burden is increased by inhaled pollutants or by drug metabolites such as acetaminophen reactive metabolite *N*-acetyl-*p*benzoquinonemine.<sup>7,14,15</sup>

Dietary antioxidant intake in early adolescence in The Republic of Macedonia is documented to be high,<sup>5</sup> which may be explained by the geographical area where it is situated and its climate. However, the oxidant burden through the passive smoke exposure is demonstrated to be high as well.<sup>5</sup>

The study was aimed to explore the relationship between acetaminophen use and asthma, hay fever, and eczema in 13/14 year old adolescents in Skopje, The Republic of Macedonia, as a developing country where acetaminophen use is not physician-controlled and passive smoke exposure is high, fruit and vegetables and cereals intake is frequent, and the prevalence of allergic diseases is moderately low.

## MATERIALS AND METHODS

The study was cross-sectional and carried out in accordance with the ISAAC Phase Three protocol,<sup>16,17</sup> in Skopje, the capital of The Republic of Macedonia, as a part of the Macedonian arm of the third phase of ISAAC.

After the consent from their parents, 3026 young adolescents 13/14 year old out of the approached 3330 from 17 randomly selected schools self-completed in their schools the ISAAC written core questionnaires on asthma, allergic rhinitis, eczema and the environmental questionnaire. A response-rate of 90.9% was achieved. The data collection was conducted outside of the main pollen season,<sup>16</sup> during the period from December, 2001 to March, 2002.

Outcome measures used in this study were the 12month prevalence rates of symptoms of asthma (current wheeze), symptoms of hay fever (current allergic rhinoconjunctivitis) and symptoms of atopic eczema (current itchy rash). These outcome measures were obtained from core questions about the presence of wheezing or whistling in the chest in the last 12 months, sneezing/runny/blocked nose accompanied with itchy-watery eyes apart from a cold or the flu in the last 12 months and about the presence of an itchy rash which was coming and going for at least 6 months at any time in the last 12 months, respectively. Information related to lifetime diagnosis of asthma, hay fever and atopic eczema was obtained from answers to questions about ever having had any physiciandiagnosed asthma, hay fever or atopic eczema (asthma 'ever', hay fever 'ever' or eczema 'ever').<sup>2,3,16,18</sup>

Acetaminophen intake in the last 12 months (current acetaminophen intake) regarding its frequency was subcategorised as never intake, infrequent intake for at least once yearly and frequent intake for at least once monthly.<sup>16</sup> Intake per week in the last 12 months of fruits and vegetables as rich sources of flavonoid and antioxidant vitamins, fish and cereals as selenium and vitamin E-rich foods (current fruits, vegetables, fish and cereals intake), indoor air-pollution (gas usually used for cooking, one or more smokers in the house) and outdoor air-pollution (trucks passage through the residential street during weekdays), as dietary sources of antioxidants and inhaled oxidants, were all used as factors for confounding acetaminophen intake adjustment.

Of all respondents, 1568 (51.8%) were boys and 1458 (48.2%) were girls. Their mean age was 13.45 years (SD 0.50); 13.46 years (SD 0.50) in boys and 13.44 years (SD 0.50) in girls.

## **Ethical Approval**

The Ethics Committee at the Medical Faculty and The Ministry of Education and Science, Skopje, The Republic of Macedonia, approved the conduct of the ISAAC Phase Three in The Republic of Macedonia.

#### **Statistical Analyses**

In accordance with the ISAAC recommendations,<sup>19</sup> missing or "any other" responses were part of the denominator for calculation of prevalence figures.

The relationship between acetaminophen intake both unadjusted and adjusted for confounding factors and current and ever-diagnosed asthma, hay fever and eczema, as dependent variables, by odds ratios with 95% confidence interval (OR, 95% CI) in binary logistic regression in SPSS 11.0 for Windows were analysed. For the questions related to asthma, hay fever and eczema missing responses were treated as negative responses whereas for the questions on environmental exposures, missing values were treated as 'missing' in the analysis. No intake of acetaminophen in the last 12 months was used as a referent category in statistical analysis. A resulting P-value of <0.05 was considered significant.

#### RESULTS

The prevalence of self-reported asthma 'ever' (1.7%) was much lower than the prevalence of current wheeze (8.8%) and more similar to the prevalence of current sleep-disturbing wheeze and speech-limiting wheeze as parameters of asthma severity (2.9% and 1.2%, respectively). Regarding the prevalence rates of hay fever 'ever' and current allergic rhinoconjunctivitis (6.7% and 5.8%, respectively) as well eczema 'ever' and current itchy rash (3.7% and 4.3%, respectively), such difference was not found.

The majority of young adolescents reported passive smoke exposure (73.1%), frequent fruits (80.9%) and cereals (86.9%) intakes. One third of the respondents were exposed to great outdoor air pollution. A frequent acetaminophen use for at least once monthly in 6.5% of the respondents only was found (Table 1).

The relationship between current acetaminophen intake and asthma, hay fever and atopic eczema is shown in Table 2.

Table 1. Prevalence of acetaminophen use and confounding factors (written questionnaire) in 3026 adolescents aged 13-14 yrs in Skopje, Republic of Macedonia, 2002

Acetaminophen use/confounding factor	n (%)
Current acetaminophen use	
never	1430 (47.3)
at least once yearly	1289 (42.6)
at least once monthly	197 (6.5)
Gas cooking at home	
no	2664 (88.0)
yes	362 (12.0)
Passive smoking at home	
no	813 (26.9)
yes	2211 (73.1)
Trucks passage through the	
residential street	
never	294 (9.7)
seldom	1660 (54.9)
frequently through the day	770 (25.4)
almost the whole day	301 (9.9)
Current fruit intake	
never/occasionally	79 (2.6)
1-2 times weekly	475 (15.7)
≥3 times weekly	2447 (80.9)
Current vegetables intake	
never/occasionally	331 (10.9)
1-2 times weekly	994 (32.8)
≥3 times weekly	1659 (54.8)
Current fish intake	
never/occasionally	1622 (53.6)
1-2 times weekly	1256 (41.5)
$\geq$ 3 times weekly	100 (3.3)
Current cereals intake	
never/occasionally	99 (3.3)
1-2 times weekly	270 (8.9)
≥3 times weekly	2631 (86.9)

Current = in the last 12 months.

\*Prevalence calculated by dividing positive responses to the given question by the total number of completed questionnaires (including missing or "any other" responses).

Symptom/disease	Current acetaminophen use at least			Current acetaminophen use at least once monthly†		
	once yearly†					
	OR	95% CI	P-value	OR	95% CI	P-value
Current wheeze						
Unadjusted	1.19	0.90-1.56	0.219	2.53	1.66-3.84	0.000
Adjusted*	1.11	0.84-1.47	0.478	2.04	1.31-3.20	0.002
Asthma 'ever'						
Unadjusted	1.78	0.97-3.28	0.065	3.06	1.25-7.48	0.014
Adjusted	1.63	0.86-3.07	0.132	2.77	1.06-7.26	0.039
Current allergic rhinoconjunctivitis						
Unadjusted	1.24	0.88-1.75	0.216	3.14	1.94-5.08	0.000
Adjusted	1.23	0.86-1.75	0.264	2.95	1.79-4.88	0.000
Hay fever 'ever'						
Unadjusted	1.35	0.99-1.83	0.060	2.26	1.38-3.69	0.001
Adjusted	1.31	0.96-1.80	0.093	2.25	1.36-3.70	0.002
Current itchy rash						
Unadjusted	1.63	1.12-2.37	0.011	1.22	0.57-2.62	0.612
Adjusted	1.59	1.08-2.34	0.020	0.93	0.41-2.10	0.853
Eczema 'ever'						
Unadjusted	1.32	0.88-1.96	0.180	1.44	0.69-2.99	0.328
Adjusted	1.22	0.81-1.85	0.341	1.16	0.54-2.53	0.701

Table 2. Relationship between acetaminophen use (unadjusted and adjusted for confounding factors) and asthma, hay fever, and eczema in 3026 adolescents aged 13-14 yrs in Skopje.

OR = Odds ratio; CI = confidence interval; Current = in the last 12 months.

\*Adjusted for sex, gas cooking exposure at home, passive smoking exposure at home, outdoor air pollutants exposure, current fruit, vegetables, fish and cereals intake.

†Current acetaminophen use at least once yearly or at least once monthly vs. never acetaminophen use.

Current wheeze, asthma 'ever', current rhinoconjunctivitis and hay fever 'ever' were all positively associated with frequent acetaminophen intake at least once monthly and the significance remained after controlling for potential confounding factors (adjusted OR 2.04, 95% CI 1.31-3.20 p = 0.002, adjusted OR 2.77, 95% CI 1.06-7.26 p = 0.039, adjusted OR 2.95, 95% CI 1.79-4.88 p = 0.000 and adjusted OR 2.25, 95% CI 1.36-3.70 p = 0.002, respectively).

Current acetaminophen intake for at least once yearly, compared to never acetaminophen intake, increased the risk of current itchy rash (adjusted OR 1.59, 95% CI 1.08-2.34 p = 0.020), but significant association regarding the more frequent acetaminophen intake and current itchy rash or infrequent and frequent acetaminophen intake and eczema 'ever' was not found (p = 0.853 or p = 0.341 and p = 0.701, respectively).

#### DISCUSSION

In this cross-sectional study we found evidence that frequent acetaminophen use may increase the risk of current and ever-diagnosed asthma and hay fever, but not atopic eczema in young adolescents. The acetaminophen intake was only weakly associated positively with ever-diagnosed asthma compared to current wheeze, current allergic rhinoconjunctivitis and ever-diagnosed hay fever. This finding may be due to a very low prevalence of self-reported physiciandiagnosed asthma 'ever', which regarding to the established prevalence rates of current wheeze, current sleep-disturbing wheeze and current speech-limiting wheeze points out that intermittent asthma in young adolescents seems to be under-diagnosed in The Republic of Macedonia.<sup>4</sup> Our findings are consistent with the previous research demonstrating a positive association between acetaminophen use and asthma and hay fever.

An ISAAC study from New Zealand has demonstrated the same results as ours in children aged 6-7 years.<sup>20</sup> Furthermore, while Shaheen et al.<sup>9</sup> in a population-based cross-sectional study have shown a clear relation between paracetamol use and asthma and rhinitis in daily and weekly adult users, we found such a relation in monthly users also, which makes the association stronger. Significantly lower risk of asthma-related outpatient visits in asthmatic children treated with ibuprofen compared with those treated with acetaminophen because of fever has been established.<sup>21</sup> Davey et al.<sup>22</sup> in a large sample of Ethiopian adults and children found a dose-related positive association between acetaminophen use and self-reported wheeze, nocturnal shortness of breath, rhinitis and eczema. Finally, in adults an increased rate of newly diagnosed asthma23 and an increased risk of asthma, COPD and decreased lung function,<sup>24</sup> all associated with a frequent acetaminophen use has been documented.

In contrast to studies that have documented an association between acetaminophen intake and eczema<sup>6,22</sup> other studies, including the present one, have not found such an association. In the population-based Avon Longitudinal Study of Parents and Children (ALSPAC), Shaheen *et al.*<sup>7,8</sup> have found that frequent paracetamol use in late pregnancy was associated with an increased risk of wheeze, but not eczema in the offspring at 18-30 months and with an increased risk of wheeze, sthma and total IgE, but not hay fever, skin test positivity or eczema in the offspring aged 7 years. No\_association between the recent use of paracetamol and eczema and only a weak association regarding the paracetamol use during the first year of life in children aged 6-7 years have been reported.<sup>20</sup>

Regarding the proposed underlying mechanisms of the positive association between acetaminophen and allergic diseases<sup>6, 9-11</sup> and the lack of its association with atopic eczema in the present study, our findings would suggest that the established increased risk of asthma and hay fever by frequent acetaminophen intake mediated through impaired is oxidant/antioxidant balance and not through an effect An alternative on atopy. explanation that acetaminophen might be taken to relieve symptoms associated with asthma and the use of asthma medications or that the positive association between

acetaminophen and allergic diseases is a result from aspirin avoidance has already been explored and found to be unlikely by studies previously published.<sup>7-9, 22-24</sup> Considering two types of relations between paracetamol and asthma - paracetamol intolerance leading to bronchospasm in analgesic-induced asthmatics and the relation of asthma with the amount or frequency of paracetamol consumption,<sup>25</sup> the first one seems an unlikely explanation as the analgesicinduced asthma in childhood occurs rarely.<sup>26</sup> Recent in vitro observations have demonstrated that clinically relevant concen-trations of acetaminophen decreased intracellular glutathione levels in human alveolar macrophages and type II pneumocytes.<sup>27</sup> Furthermore, a decrease in serum total antioxidant capacity after regular paracetamol ingestion in therapeutic doses in healthy volunteers<sup>28</sup> and reduced antioxidant status and erythrocyte glutathione concentrations after repeated supratherapeutic doses of paracetamol in febrile children have recently been reported.<sup>29</sup> Finally, it is anticipated that reduced endogenous antioxidant capacity, as assessed by glutathione S-transferase genotype, or exposure to higher levels of exogenous inhaled oxidants after paracetamol exposure would provide susceptibility for developing asthma.<sup>15</sup>

There are a limited number of studies concerning the recently developed paracetamol hypothesis. While most of them have been conducted in developed countries, to the best of our knowledge, the present study is the second one performed in a developing country where awareness of the adverse effects of aspirin in asthmatic patients and the use of asthma medications are both relatively low, which makes the reverse causation of the established association between acetaminophen and asthma and hay fever less likely.<sup>13</sup> Another advantage of the study is the large sample investigated and a high response-rate achieved. The current study has some limitations as well. Like in other questionnaire-based studies there is a possibility information bias. However, the ISAAC of standardised and validated questionnaires are questionnaires, accompanied by validated study protocol.<sup>30</sup> Furthermore, in the ISAAC environmental questionnaire there is a lack of more detailed information on frequency of acetaminophen intake or its dosage or intake of compound preparations containing acetaminophen, which may influence the results of our study. However, as the positive association between acetaminophen use for at least once monthly and asthma and hay fever has been established in our study, it is likely that a stronger association would have to be demonstrated if more frequent acetaminophen intake or intake of acetaminophen in compound preparations would be considered.

In conclusion, the findings of this questionnairebased study in young adolescents in The Republic of Macedonia, as a country with a moderately low prevalence of allergic diseases and acetaminophen intake, high tobacco smoke exposure and dietary antioxidant intake, are further support to the paracetamol (acetaminophen) hypothesis regarding asthma and hay fever that is coming from a developing country. The impaired oxidant/antioxidant balance in airways by acetaminophen and not promotion of atopy is a proposed underlying mechanism of the established relationship. The results derived from the present study are sufficient for caution to the frequent acetaminophen use. Until further epidemiological and biological research results come, acetaminophen remains a preferred analgesic and antipyretic in childhood, but only if physician-recommended within therapeutic doses and used not frequently.

### ACKNOWLEDGMENTS

The authors would like to thank young adolescents for their participation in the survey and principals, psychologists, teachers from the selected schools for their collaborations. The Ministry of Education and Science of The Republic of Macedonia provided financial support for the study.

#### REFERENCES

- Masoli M, Fabian D, Holt S, Beasley R for the Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004; 59(5):469-78.
- Strachan DP, Sibbald B, Weiland SK, Ait-Khaled N, Anabwani G, Anderson HR, et al. Worldwide variation in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997; 8(4):161-76.
- 3. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the

International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103(1 pt 1):125-38.

- 4. Vlaski E, Stavric K, Isjanovska R, Seckova L, Kostovski A, Kimovska M. Prevalence and severity of asthma, allergic rhinitis and eczema in school children in Skopje (International Study of Asthma and Allergies in Childhood phase 3). Macedonian Journal of Medicine 2005; 51:24-34.
- Vlaski E, Stavric K, Isjanovska R, Seckova L, Kimovska M. Overweight hypothesis in asthma and eczema in young adolescents. Allergol Immunopathol (Madr) 2006; 34(5):199-205.
- Newson RB, Shaheen SO, Chinn S, Burney PG. Paracetamol sales and atopic disease in children and adults: an ecological analysis. Eur Respir J 2000; 16(5):817-23.
- Shaheen SO, Newson RB, Sherriff A, Henderson AJ, Heron JE, Burney PG, et al. Paracetamol use in pregnancy and wheezing in early childhood. Thorax 2002; 57(11):958-63.
- Shaheen SO, Newson RB, Henderson AJ, Headley JE, Stratton FD, Jones RW, et al. ALSPAC Study Team. Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood. Clin Exp Allergy 2005; 35(1):18-25
- Shaheen SO, Sterne JA, Songhurst CE, Burney PG. Frequent paracetamol use and asthma in adults. Thorax 2000; 55(4):266-70.
- Eneli I, Sadri K, Camargo C, Barr RG. Acetaminophen and the risk of asthma: the epidemiologic and pathophysiologic evidence. Chest 2005; 127(2):604-12.
- Varner AE, Busse WW, Lemanske RF Jr. Hypothesis: decreased use of pediatric aspirin has contributed to the increasing prevalence of childhood asthma. Ann Allergy Asthma Immunol 1998; 81(4):347-51.
- Varner A. Paracetamol and asthma. Thorax 2000; 55(10):882-3
- Allmers H. Frequent acetaminophen use and allergic diseases: is the association clear? J Allergy Clin Immunol 2005; 116(4):859-62.
- 14. Shaheen SO, Sterne JAC, Thompson RL, Songhurst CE, Margetts BM, Burney PG. Dietary antioxidants and asthma in adults: population-based case-control study. Am J Respir Crit Care Med 2001; 164(10 Pt 1):1823-8
- 15. Fogarty A, Davey G. Paracetamol, antioxidants and asthma. Clin Exp Allergy 2005; 35(6):700-2.

- 16. Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW, on behalf of the ISAAC Steering Committee and the ISAAC Phase Three Study Group. ISAAC Phase Three Manual. Auckland, New Zealand: ISAAC International Data Centre, 2000.
- 17. Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW, and the ISAAC Steering Committee. The International Study of Asthma and Allergies in Childhood (ISAAC): Phase Three rationale and methods. Int J Tuberc Lung Dis 2005; 9(1):10-6.
- The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12:315-35.
- 19. ISAAC Phase Three Newsletter. Auckland, New Zealand, December 2001.
- Cohet C, Cheng S, MacDonald C, Baker M, Foliaki S, Huntington N, et al. Infections, medication use, and the prevalence of symptoms of asthma, rhinitis, and eczema in childhood. J Epidemiol Community Health 2004; 58(10):852-7.
- Lesko SM, Louik C, Vezina RM, Mitchell AA. Asthma morbidity after the short-term use of ibuprofen in children. Pediatrics 2002; 109(2):E20.
- 22. Davey G, Berhane Y, Duncan P, Aref-Adib G, Britton J, Venn A. Use of acetaminophen and the risk of selfreported allergic symptoms and skin sensitization in Butajira, Ethiopia. J Allergy Clin Immunol 2005; 116(4):863-8.
- 23. Barr GR, Wentowski CC, Curhan CG, Somers CS, Stampfer JM, Schwartz J, et al. Prospective study of

acetaminophen use and newly diagnosed asthma among women. Am J Respir Crit Care Med 2004; 169(7):836-41.

- 24. McKeever TM, Lewis SA, Smit HA, Burney P, Britton JR, Cassano PA. The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. Am J Respir Crit Care Med 2005; 171(9):966-71.
- 25. Karakaya G, Lakyoncu AF. Paracetamol and asthma. Expert Opin Pharmacother 2003; 4(1):13-21.
- GINA Workshop Report. Global Strategy for Asthma Management and Prevention. NIH Publication No 02-3659, Updated 2005. Available from URL: http://ginasthma.org.
- 27. Dimova S, Hoet PH, Dinsdale D, Nemery B. Acetaminophen decreases intracellular glutathione levels and modulates cytokine production in human alveolar macrophages and type II pneumocytes in vitro. Int J Biochem Cell Biol 2005; 37(8):1727-37.
- Nuttall SL, Khan JN, Thorpe GH, Langford N, Kendall MJ. The impact of therapeutic doses of paracetamol on serum total antioxidant capacity. J Clin Pharm Ther 2003; 28(4):289-94.
- 29. Kozer E, Evans S, Barr J, Greenberg R, Soriano I, Bulkowstein M, et al. Glutathione, glutathione-dependent enzymes and antioxidant status in erythrocytes from children treated with high dose paracetamol. Br J Clin Pharmacol 2003; 55(3):234-40.
- 30. Worldwide variations in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351(9111):1225-32.